HITTS. Heparin-Induced Thrombotic Thrombocytopenia Syndrome

Cardiac Anesthesiologist

 Heparin-Induced Thrombotic Thrombocytopenia Syndrome (HITTS) is a prothrombotic disorder caused by IgG mediated antibodies to complexes of platelet factor 4 (PF4) and heparin.

Diagnosis

The detection of HITTS antibodies plus one of the following.

  •  unexplained drop in platelet count by 30-50%

  •  venous or arterial thrombosis

  •  skin lesions at heparin injection site

  •  anaphylactoid reactions

The antibodies bind to the PF4-heparin complexes on the platelet surface inducing activation. The activated platelets increase the release and surface expression of PF4, creating a positive feedback loop in which further release of PF4 promotes further platelet activation.

Warfarin can induce a paradoxical, hypercoagulable state usually within 3 to 10 days of therapy initiation, associated with inadequate heparin overlap, and thought to be due to an imbalance between anticoagulant and procoagulant pathways. The anticoagulants protein C and protein S have a shorter half-life than other vitamin K–dependent factors (II, IX, and X), resulting in a deficiency of both proteins early in treatment. This increases the chance of thrombosis and subsequent skin necrosis.

 

Alternative anticoagulants during cardio-pulmonary bypass (CPB) :

Direct thrombin inhibitor (half-life 25 min)

Bivalirudin 1mg/kg IV, followed by 2.5mg/kg/hr. Use additional boluses of 0.5-1mg/kg to maintain ACT 2.5 x baseline or > 600s or APTT ~ 200s.

Cease the infusion 15 min prior to planned separation.

Use ecarin clotting times to monitor to target blood concentration 15mcg/mL.

Factor Xa inhibitor (half-life 18-24 hours)

Danaparoid 7500 units with 1500 units in prime to achieve a level of at least 1 unit/mL

during CPB. ACT does not correlate with anti-Xa activity.

Antiplatelet agent plus heparin

Tirofiban 10mcg/kg bolus with infusion 0.15mcg/kg/min followed by heparin

400 IU/kg (Restore protocol).

Minimise stagnant blood in circuit and cardiotomy suction, and continually flush cardioplegia circuit.

Management during cardio-pulmonary bypass (CPB) :

1 Stop heparin, defer procedure and come off bypass if practical.

2 Urgently source alternative anticoagulants.

3 Scan for clot within circuit 21 , avoid stasis, maintain circuit flow and give volume.

4 Monitor for oxygenator failure 32 .

5 Monitor lactate for evidence of organ malperfusion.

6 Do not give platelets.

7 Use sodium citrate as anticoagulant for cell salvage.

8 Send blood for platelet factor 4/polyanion antibody assay and platelet activation test.

9 Prepare for significant postbypass bleeding.

10 Avoid postoperative warfarin until platelet count recovered.

 

Leave a Reply

Your email address will not be published. Required fields are marked *